Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Friday, Figs Inc. (NYSE:FIGS), a healthcare apparel company, chose to reject a buyout offer from Story3, a private equity firm. The proposal, which was initially valued at over $1 billion, or $6 per share, was turned down as Figs remains optimistic about its independent strategy and future prospects.
The company's strong balance sheet, with more cash than debt and an impressive current ratio of 4.58, supports its standalone strategy. The announcement was made public through a form 8-K filing. InvestingPro analysis reveals 12 key investment tips for FIGS, available to subscribers.
The decision to stay public follows reports from just over a week ago that Ron Baron, a leading shareholder, objected to the acquisition. Instead of supporting the buyout, Baron is set to increase his stake in Figs by purchasing shares from Thomas Tull, another significant shareholder. This move is expected to raise Baron's ownership to approximately 36%. The company maintains impressive gross profit margins of 67.67%, suggesting strong operational efficiency.
KeyBanc analyst Ashley Owens maintained a Sector Weight rating on Figs stock, indicating a neutral stance. Owens referred to a previous note from November 14, 2024, which detailed the company's near-term and medium-term strategies and growth opportunities. Despite the recent developments, KeyBanc's rating for Figs remains unchanged.
Owens pointed out that Figs is trading at 13.4 times its 2025 estimated enterprise value to EBITDA (EV/EBITDA) and 1.4 times its 2025 estimated EV to sales. These metrics are compared to the Apparel & Ecommerce brands peer group, which trades at an average of 10.4 times EV/EBITDA and 1.3 times EV/sales. According to the analysis, Figs' valuation is considered fair, reflecting the company's robust growth profile and substantial total addressable market (TAM).
On January 16, 2025, Figs stock closed at $6.12, slightly above the buyout offer price, indicating some investor confidence in the company's standalone plan. With an overall Financial Health score rated as GOOD by InvestingPro, and its next earnings report due on February 26, 2025, investors will be watching closely. KeyBanc's assessment suggests that the current market valuation of Figs aligns with its growth expectations and industry benchmarks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.